Zusammenfassung
Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Krankheiten. Hauptindikationen sind arterielle Hypertonie, koronare Herzkrankheit, tachykarde Herzrhythmusstörungen und chronische Herzinsuffizienz. Wichtigste Gruppe sind die β1-selektiven Betarezeptorenblocker.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aursnes I, Osnes J-B, Tvede IF, Gasemyr J, Natvig B (2007): Does atenolol differ from other ß-adrenergic blockers? BMC Clin Pharmacol 7:4
Arzneimittelkommission der deutschen Ärzteschaft (2009): 23. Arterielle Hypertonie: Arzneiverordnungen. 22. Aufl., Medizinische Medien Informations GmbH, Neu-Isenburg: S 597628
Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013): Sytematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168: 3572–3579
Beevers DG (2005): The end of beta blockers for uncomplicated hypertension? Lancet 366: 1510–1512
Bell DS, Lukas MA, Holdbruck FK, Fowler MB (2006): The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 22: 287–296
Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38: 199–204
Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013): Benefits of ß blockers in patients with heart failure and reduced ejec- tion fraction: network meta-analysis. BMJ 346: f596
Chobanian AV, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute;. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). JAMA 289: 2560-72. Erratum in: JAMA 2003, 920:19–7
CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13
Contini M, Apostolo A, Cattadori G, Paolillo S, Iorio A, Bertella E, Salvioni E, Alimento M, Farina S, Palermo P, Louercio M, Manzegazza V, Karten M, Sciomer, S, Magri D, Fiorentini C, Agpstini P (2013). Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial. Int J Cardiol 168: 2134–2140
Dargie HJ (2003): ß-Blockers in heart failure. Lancet 362: 2–3
Deutsche Hochdruckliga - Deutsche Hypertonie Gesellschaft (2008): Leitlinien zur Behandlung der arteriellen Hypertonie. Stand Juni 2008. http: //www.leitlinien.net'046-001.pdf
Deutsche Hochdruckliga, Deutsche Gesellschaft für Hypertonie und Prävention. (2011). DHL- Leitlinien-update 2011. http://www.hochdruckliga.de/tl_files/content/dhl/downloads/DHL-Leitlinien-2011.pdf
DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH (2013). Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol 111: 765–769
DiNIcolantonio JJ, Fares H, Niazi AK, et al. (2015): ß-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the Literature. Open Heart 21(1): e00023–0
Eschenhagen T, Erdmann E (2010): 16. Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 22924–3
Flather MC, Shibata MC, Coats AJS et al (2005): Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215–225
Grundt C, Meier K, Grundt A, Lemmer B (2007): Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25: 1001–1007
Hohlfeld T, Kelm M (2010): 17. Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 245–257
Hoppe UC, Erdmann E (2010): Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35:535–541
Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014): Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223–230
Kreutz R, Kolloch R (2010): Arterielle Hypertonie. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 197–218
Leaute-Labreze C, Hoeger P, Mazereew-Hautier J, et al. (2015): A randomized, controlled trial of propranolol in infantile hemangioma. N Eng J Med 19:735–746
Lindholm LH, Carlberg B, Samuelsson O (2005): Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553
McMurray J (2005): Making sense of SENIORS. Eur Heart J 26: 203–206
MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001–2007
Moen MD, Wagstaff AJ (2006): Nebivolol - a review of its use in the management of hypertension and chronic heart failure. Drugs 66: 1389–1409
National Institute for Health and Care Excellence (NICE) (2011): Hypertension - Clinical
management of primary hypertension in adults. Issued: August 2011 .NICE clinical guide- line 127: Internet: guidance.nice.org.uk/cg127
Nationale VersorgungsLeitlinie (2013): Chronische Herzinsuffizienz. http://www.leitlinien.de/>nvl/herzinsuffizienz
Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658
Poole-Wilson PA, Svedberg K, Cleland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Com- parison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7–13
POISE Study Group (2008): Effects of extended-release metoprolol succinate in patients under- going non-cardiac surgery (POISE trial) a randomized controlled trial. Lancet 371: 1839184–7
Sackner-Bernstein J (2005): Reducing the risks of sudden death and heart failure post myo- cardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28 (11 Suppl 1): I19–27
Salpeter S, Ormiston T, Salpeter E, Wood-Baker R (2006): Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, The Cochrane Collaboration Volume (1), 2006
Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104: 511–514
Vestbo J, Hurd SS, Augusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Mar- tinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. (2013). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med. 187: 347–365
Wiysonge CS, Bradley HA, J V, Mayosi MB, Mbewu A, Opie LH. (2012). Beta-blockers for hypertension. Cochrane Database Syst Rev. Nov 14: CD00200–3
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lemmer, B. (2015). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-662-47186-9_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47185-2
Online ISBN: 978-3-662-47186-9
eBook Packages: Medicine (German Language)